Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals, Inc.

NNASDAQ:PCSA
1.72
USD
-0.14
(-7.53%)
-5.46EPS
5.36MMarket Cap
Mar 03Next Earn

Total Valuation

USD

As of June 30, 2026, Processa Pharmaceuticals, Inc. carries a market capitalization of 5.36M, placing it among publicly traded companies globally. Its enterprise value stands at 4.70M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap5.36M
Enterprise Value4.70M

Important Dates

Processa Pharmaceuticals, Inc.'s next confirmed earnings release is scheduled for March 3, 2027.

Earnings Date3/3/2027

Share Statistics

As of June 30, 2026, Processa Pharmaceuticals, Inc. has 2.79M shares outstanding.

Shares Outstanding2.79M

Valuation Ratios

These figures are as of June 30, 2026.

PB Ratio-16.90
P/TBV Ratio-16.90
P/FCF Ratio-0.39
P/OCF Ratio-0.39

Financial Position

As of June 30, 2026, Processa Pharmaceuticals, Inc. maintains a current ratio of 0.87, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities.

Current Ratio0.87
Quick Ratio0.28

Financial Efficiency

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -262.17, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 11.50, a quick read on workforce productivity versus industry peers.

Return on Assets (ROA)-262.17
Employee Count11.50

Stock Price Statistics

USD

As of the close on November 16, 2026, Processa Pharmaceuticals, Inc.'s stock has declined approximately 77.07% over the past 52 weeks. The 50-day moving average sits at 1.80, while the 200-day moving average is 2.29.

52-Week Price Change-77.07%
50-Day Moving Average1.80
200-Day Moving Average2.29

Income Statement

USD

Over the twelve months ended June 30, 2026, Processa Pharmaceuticals, Inc. generated - - in revenue and converted that into -13.44M in net income, yielding earnings per share of -5.46. EBITDA reached -12.86M, while operating income came in at -12.86M.

Operating Income-12.86M
Pretax Income-13.44M
Net Income-13.44M
EBITDA-12.86M
EBIT-12.86M
Earnings Per Share (EPS)-5.46

Balance Sheet

USD

These figures are as of June 30, 2026. Total book value stands at -317,341.00, with working capital of -320,551.00 providing operational flexibility.

Cash & Cash Equivalents668,328.00
Net Debt-196,325.00
Equity (Book Value)-317,341.00
Book Value Per Share-0.11
Working Capital-320,551.00

Cash Flow

USD

Processa Pharmaceuticals, Inc. produced -11.97M in operating cash flow over the twelve months ended June 30, 2026. After subtracting - - in capital expenditures, free cash flow totaled -11.97M - equivalent to -4.86 per share.

Operating Cash Flow-11.97M
Free Cash Flow-11.97M
FCF Per Share-4.86

Dividends & Yields

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -253.29: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -119.23, meaning Processa Pharmaceuticals, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-119.23
FCF Yield-253.29

Stock Splits

Processa Pharmaceuticals, Inc.'s most recent stock split took place on December 17, 2025 with a 25:1 split ratio.

Last Split Date12/17/2025
Split Ratio25:1

Scores

As of June 30, 2026, Processa Pharmaceuticals, Inc. has an Altman Z-Score of -92.01, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-92.01